Anande, G.* ; Deshpande, N.P.* ; Mareschal, S.* ; Batcha, A.M.N.* ; Hampton, H.R.* ; Herold, T. ; Lehmann, S.* ; Wilkins, M.R.* ; Wong, J.W.H.* ; Unnikrishnan, A.* ; Pimanda, J.E.*
RNA splicing alterations induce a cellular stress response associated with poor prognosis inAcute Myeloid Leukemia.
Clin. Cancer Res. 26, 3597-3607 (2020)
Purpose: RNA splicing is a fundamental biological process that generates protein diversity from a finite set of genes. Recurrent somatic mutations of splicing factor genes are common in some hematologic cancers but are relatively uncommon in acute myeloid leukemia (AML, < 20% of patients). We examined whether RNA splicing differences exist in AML, even in the absence of splicing factor mutations.Experimental Design: We developed a bioinformatics pipeline to study alternative RNA splicing in RNA-sequencing data from large cohorts of patients with AML.Results: We have identified recurrent differential alternative splicing between patients with poor and good prognosis. These splicing events occurred even in patients without any discernible splicing factor mutations. Alternative splicing recurrently occurred in genes with specific molecular functions, primarily related to protein translation. Developing tools to predict the functional impact of alternative splicing on the translated protein, we discovered that approximately 45% of the splicing events directly affected highly conserved protein domains. Several splicing factors were themselves misspliced and the splicing of their target transcripts were altered. Studying differential gene expression in the same patients, we identified that alternative splicing of protein translation genes in ELNAdv patients resulted in the induction of an integrated stress response and upregulation of inflammation-related genes. Finally, using machine learning techniques, we identified a splicing signature of four genes which refine the accuracy of existing risk prognosis schemes and validated it in a completely independent cohort.Conclusions: Our discoveries therefore identify aberrant alternative splicing as a molecular feature of adverse AML with clinical relevance.
Altmetric
Additional Metrics?
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Corresponding Author
Keywords
Older Patients; Mutations; Risk; Stem; Recommendations; Identification; Hematopoiesis; Modulation; Management; Catalysis
Keywords plus
ISSN (print) / ISBN
1078-0432
e-ISSN
1557-3265
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 26,
Issue: 14,
Pages: 3597-3607
Article Number: ,
Supplement: ,
Series
Publisher
American Association for Cancer Research (AACR)
Publishing Place
615 Chestnut St, 17th Floor, Philadelphia, Pa 19106-4404 Usa
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)
Grants
Federal Ministry of Education & Research (BMBF)
German Research Foundation (DFG)
German Cancer Consortium (DKTK)
Leukemia and Lymphoma Society
Translational Cancer Research Network